Hypermobility: Here's What Providers Should Know About Their Patients

Why do some hypermobile patients keep coming back with the same injuries? Are we overlooking deeper connective tissue issues? And can regenerative treatments really make a long-term difference in stability and pain? In this conversation, we dive into hypermobility and here's what providers should know about their patients—from understanding the spectrum of hypermobility syndrome to tailoring hypermobility treatment strategies that address both physical and neurological factors. Drawing on years of experience treating complex connective tissue disorder cases, including ehlers-danlos syndromes, we explore realistic ehlers danlos syndrome treatment options, treatment for hypermobility, and practical insights for how to help hypermobility patients thrive. I walk you through not just what is hypermobility, but also when movement therapy should take priority over injections, and where orthobiologics fit into the bigger picture. You’ll hear nuanced perspectives on regenerative medicine, regenerative medicine orthopedics, and how to match orthobiologic treatments—like regenerative injection therapy, regenerative joint therapy, and regenerative orthopedic medicine—to the right pathology. From identifying early warning signs in patient histories, to deciding between prolotherapy and PRP, to using supportive tools like orthotics and bracing, this episode is packed with practical takeaways that you can apply right away. We also tackle the ethical side of treating hypermobility and EDS with limited research. You’ll learn why transparency in expectations is essential, how to differentiate between injury and pain, and the importance of integrating psychological support for patients with central sensitization. Whether you’re considering orthobiologics for shoulder instability in athletes, managing recurring joint subluxations, or simply trying to understand how to better evaluate and track hypermobile patients, this discussion gives you a deeper framework to guide decision-making. By the end, you’ll have actionable strategies to improve diagnostic precision, select the right regenerative therapies, and create multi-disciplinary care plans that address both joint mechanics and nervous system sensitivity. This is not about promising miracles—it’s about making informed, ethical choices that can reasonably improve patient function and quality of life. If this conversation resonates with you, make sure to subscribe, hit the like button, drop a comment with your own experience treating hypermobility, and share this with a colleague who works with EDS or connective tissue disorders.